This latest Phase II trial is an international, multi-center, double-blind and placebo-controlled study of SA4503 in patients with stroke with a planned enrollment of approximately 60 patients. The primary objective of the study is to evaluate safety of SA4503 in this patient population.
SA4503 is a potent and selective agonist of the sigma-1 receptor that is associated with enhancement of recovery in experimental models of stroke. SA4503 induces neuroregeneration and facilitates the recovery of damaged tissues from stress or ischemia-induced insults.
Shiro Mita, chairman and CEO of MSC, said: “Stroke poses significant therapeutic challenges. SA4503 with its unique and unexploited mechanism has the potential to address the limitations of today’s stroke therapies.”